-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Reinstates Buy on Krystal Biotech, Announces $441 Price Target

Benzinga·09/24/2026 12:56:46
Listen to the news
Goldman Sachs analyst Andrea Newkirk reinstates Krystal Biotech (NASDAQ:KRYS) with a Buy and announces $441 price target.